中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
25期
21-23
,共3页
王利惠%郝冬琳%吴文%季莉莉%王佳佳
王利惠%郝鼕琳%吳文%季莉莉%王佳佳
왕리혜%학동림%오문%계리리%왕가가
硫辛酸%脑梗死%高同型半胱氨酸血症
硫辛痠%腦梗死%高同型半胱氨痠血癥
류신산%뇌경사%고동형반광안산혈증
Lipoic acid%Ischemic stroke%Hyperhomocysteinemia
目的:观察α-硫辛酸治疗急性脑梗死伴高同型半胱氨酸血症患者的临床疗效。方法:将80例急性脑梗死伴高同型半胱氨酸血症的患者按照随机数字表法分为治疗组和对照组各40例,在试验前均未给予溶栓治疗。两组患者均根据病情给予常规治疗,治疗组在常规治疗基础上加用α-硫辛酸注射液600 mg加入0.9%氯化钠250 mL静滴,1次/d,14 d为一疗程。分别在治疗前、治疗后评定两组患者的NIHSS评分和血清同型半胱氨酸水平,在12周时评定两组患者的日常生活活动能力(ADL)评分和改良Rankin评分(MRS)。结果:1个疗程治疗结束后,治疗组的NIHSS评分(2.75±0.90)分明显低于对照组的(3.85±2.36)分(P<0.01)。治疗组的血清同型半胱氨酸(10.99±1.77)μmol/L明显低于对照组的(11.88±1.20)μmol/L(P<0.01)。12周时,治疗组ADL评分巴氏指数(Barthel Index)为(86.38±6.79)分,明显高于对照组的(81.00±12.10)分(P<0.05),治疗组的MRS评分(1.05±0.71)分明显低于对照组的(1.63±0.70)分(P<0.01)。结论:α-硫辛酸治疗急性脑梗死伴高同型半胱氨酸血症的患者临床疗效显著,有较好的应用前景。
目的:觀察α-硫辛痠治療急性腦梗死伴高同型半胱氨痠血癥患者的臨床療效。方法:將80例急性腦梗死伴高同型半胱氨痠血癥的患者按照隨機數字錶法分為治療組和對照組各40例,在試驗前均未給予溶栓治療。兩組患者均根據病情給予常規治療,治療組在常規治療基礎上加用α-硫辛痠註射液600 mg加入0.9%氯化鈉250 mL靜滴,1次/d,14 d為一療程。分彆在治療前、治療後評定兩組患者的NIHSS評分和血清同型半胱氨痠水平,在12週時評定兩組患者的日常生活活動能力(ADL)評分和改良Rankin評分(MRS)。結果:1箇療程治療結束後,治療組的NIHSS評分(2.75±0.90)分明顯低于對照組的(3.85±2.36)分(P<0.01)。治療組的血清同型半胱氨痠(10.99±1.77)μmol/L明顯低于對照組的(11.88±1.20)μmol/L(P<0.01)。12週時,治療組ADL評分巴氏指數(Barthel Index)為(86.38±6.79)分,明顯高于對照組的(81.00±12.10)分(P<0.05),治療組的MRS評分(1.05±0.71)分明顯低于對照組的(1.63±0.70)分(P<0.01)。結論:α-硫辛痠治療急性腦梗死伴高同型半胱氨痠血癥的患者臨床療效顯著,有較好的應用前景。
목적:관찰α-류신산치료급성뇌경사반고동형반광안산혈증환자적림상료효。방법:장80례급성뇌경사반고동형반광안산혈증적환자안조수궤수자표법분위치료조화대조조각40례,재시험전균미급여용전치료。량조환자균근거병정급여상규치료,치료조재상규치료기출상가용α-류신산주사액600 mg가입0.9%록화납250 mL정적,1차/d,14 d위일료정。분별재치료전、치료후평정량조환자적NIHSS평분화혈청동형반광안산수평,재12주시평정량조환자적일상생활활동능력(ADL)평분화개량Rankin평분(MRS)。결과:1개료정치료결속후,치료조적NIHSS평분(2.75±0.90)분명현저우대조조적(3.85±2.36)분(P<0.01)。치료조적혈청동형반광안산(10.99±1.77)μmol/L명현저우대조조적(11.88±1.20)μmol/L(P<0.01)。12주시,치료조ADL평분파씨지수(Barthel Index)위(86.38±6.79)분,명현고우대조조적(81.00±12.10)분(P<0.05),치료조적MRS평분(1.05±0.71)분명현저우대조조적(1.63±0.70)분(P<0.01)。결론:α-류신산치료급성뇌경사반고동형반광안산혈증적환자림상료효현저,유교호적응용전경。
Objective:To observe the clinical efficacy ofα-lipoic acid injection in treatment of acute cerebral infarction patients with hyperhomocysteinemia (Hhcy).Method:80 cerebral infarction patients with Hhcy were randomly divided into the treatment group and the control group,40 cases in each group.All the patients were not given thrombolysis anticoagulation therapy before the trial.The two groups were given routine treatment. Additionally,the treatment group received treatment of injection lipoic acid 600 mg,which was added into 250 mL 0.9%NaCl solution injection,by intravenous drip infusion once daily for 14 days.The neurological dysfunction was assessed by National Institutes of Health Stroke Scale (NIHSS).Stroke disability was evaluated by Barthel Index (BI) score and Modified Rankin Scale(MRS) after 12 weeks.Result:After one course of treatment,The mean NIHSS of the treatment group was (2.75±0.90)score,it was significantly lower than (3.85±2.36)score of the control group(P<0.01).The homocysteine level of the treatment group was(10.99±1.77)μmol/L,it was significantly lower than (11.88±1.20)μmol/L of the control group(P<0.01).The Barthel Index of ADL in treatment group was (86.38±6.79)score,it was significantly higher than (81.00±12.10)score in the control group(P<0.05),the mean MRS of the treatment group was (1.05±0.71)score,it was significantly lower than (1.63±0.70)score of the control group(P<0.01).Conclusion:The clinical curative effect of α-lipoic acid injection therapy in treatment of acute cerebral infarction patients with hyperhomocysteinemia is remarkable,and has a good application prospect.